original ) (raw )Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes
Michelle Bound
Diabetes & vascular disease research, 2017
View PDFchevron_right
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Juliana Chan
The New England journal of medicine, 2017
View PDFchevron_right
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
Dawn Nicewarner
Cardiovascular …, 2011
View PDFchevron_right
Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance
Federico Bellavere
Journal of the Endocrine Society, 2018
View PDFchevron_right
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Michael Trautmann
The Journal of Clinical Endocrinology & Metabolism, 2011
View PDFchevron_right
Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus
cych samson
Journal of the Formosan Medical Association, 2013
View PDFchevron_right
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
Gisela Robles
Drug Design, Development and Therapy, 2009
View PDFchevron_right
Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting
Ory Marrioneaux
Diabetes technology & therapeutics, 2009
View PDFchevron_right
Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes
Richard Bergenstal
The American Journal of Medicine, 2010
View PDFchevron_right
Rationale and Design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) Trial
Juliana Chan
American Heart Journal, 2015
View PDFchevron_right
Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data
Michael Trautmann
Clinical Therapeutics, 2016
View PDFchevron_right
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Michael Trautmann
The Lancet, 2008
View PDFchevron_right
Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
Carrie McAdam-marx
Diabetes, Obesity and Metabolism, 2009
View PDFchevron_right
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
Gilbert Ramirez
Vascular Health and Risk Management, 2012
View PDFchevron_right
Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
muhammad S khan
Journal of Diabetes Research, 2015
View PDFchevron_right
Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure
maria luisa sardu
Clinical Pharmacology & Therapeutics, 2020
View PDFchevron_right
One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice
P. Selvais , M. Ponchon
Diabetes & Metabolism, 2010
View PDFchevron_right
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes
Byron Hoogwerf
Annals of Internal Medicine, 2007
View PDFchevron_right
Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
Michael Trautmann
The Journal of Clinical Endocrinology & Metabolism, 2005
View PDFchevron_right
The Efficacy and Tolerability of Exenatide in Comparison to Placebo; A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Pooneh Salari
View PDFchevron_right
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
Mark Fineman
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005
View PDFchevron_right
Efficacy and Safety of Exenatide versus Insulin in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis
IJMESS JOURNAL
International Journal of Management, Economics and Social Sciences , 2019
View PDFchevron_right
Association of blood pressure and body weight decline during one-year treatment with the incretin analogue exenatide
Maja Baretić
2013
View PDFchevron_right
Exenatide Alters Myocardial Glucose Transport and Uptake Depending on Insulin Resistance and Increases Myocardial Blood Flow in Patients with Type 2 Diabetes
Jørgen Rungby
The Journal of Clinical Endocrinology & Metabolism, 2012
View PDFchevron_right
Effects of Exenatide on both fat mass loss and cardiometabolic risk in obese subjects with type 2 diabetes mellitus
Carmen Colica
2017
View PDFchevron_right